| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Data to be Presented in Four Oral Presentations and Posters at the 2023 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
Supports neffy's potential to be a safe and effective option across patient sub-populations based on data including the relationship between BMI/body weight and epinephrine exposure, congestion/rhinitis during upper respiratory tract infection, and pediatrics
SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that clinical data supporting neffy (epinephrine nasal spray) will be presented during the 2023 American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting. The meeting is being held November 9-13, 2023, in Anaheim, California.
Presentations will highlight clinical data from a rigorous registration program for neffy 2.0 mg of more than 600 subjects, including analyses of patients with upper respiratory tract infections, pediatric patients ≥30 kg with a history of type I allergic reaction, patients with allergen-induced allergic rhinitis and the relationship between body weight/BMI and epinephrine exposure.
Notably, data demonstrate that the pharmacokinetics of neffy are independent of BMI or body weight. Unlike injection products where exposures decreased with varying BMI or body weight, neffy could be a potentially effective epinephrine product in these patients. These results will be presented as a Distinguished Industry Oral Abstract on Saturday, November 11 at 4:30 PM PT (Session A).
"At ARS Pharma, we are committed to advancing much-needed science in allergic diseases to make a positive impact on the people and communities we serve. To that end, we are pleased to share these clinical data that provide critical insights into neffy's potential as the first intranasal medicine for treating severe allergic reactions," said Sarina Tanimoto, M.D., Ph.D., Chief Medical Officer and Co-Founder of ARS Pharma. "Severe allergic reactions can be life-threatening, and today's standard of care is needle-bearing injectable devices associated with numerous administration challenges. The data generated supports that neffy achieves a PK/PD profile comparable to injectable products across various patient subgroups while potentially allowing patients to easily carry and confidently administer epinephrine without hesitation or anxiety."
Details of the presentations are as follows:
Title: Acute Allergic Rhinitis Increases Endogenous Epinephrine Resulting in Increased Heart Rate
Date & Time: Friday, November 10 at 4:30 PM PT
Session: Adverse Drug Reactions, Insect Reactions, Anaphylaxis
Data Summary: Acute allergic rhinitis induces increases in circulating endogenous epinephrine and heart rate, possibly in response to changes in the distribution of blood flow.
Title: A Single-Period, Single-Dose Study of the Pharmacokinetics of Epinephrine After Administration ARS-1 to Pediatric Subjects
Date & Time: Friday, November 10 at 5:45 PM PT
Session: Adverse Drug Reactions, Insect Reactions, Anaphylaxis
Data Summary: The pharmacokinetic profile of neffy 2.0 mg in pediatric allergy subjects is comparable to what has been observed in adults and is expected to be a safe and effective option for the treatment of type I allergic reactions (including anaphylaxis) in pediatric subjects.
Title: Integrated Pharmacokinetic-Pharmacodynamic Analysis: Effect of Weight and BMI on Epinephrine Concentration
Date & Time: Saturday, November 11 at 4:30 PM PT
Session: Distinguished Industry Oral Abstracts – Session A
Data Summary: Based on the rigorous registration program of neffy, the presentation will address the question about what is the effect of body weight and BMI on epinephrine absorption. Intramuscular and subcutaneous injections have a negative relationship with epinephrine exposures while neffy does not. This suggests neffy could be a potentially more effective epinephrine alternative to injection products in patients with elevated body weight or BMI.
Title: Effect of Upper Respiratory Tract Infection on the Pharmacokinetics of Intranasal Epinephrine
Date & Time: Adverse Drug Reactions, Insect Reactions, Anaphylaxis
Session: Sunday, November 12 at 11:35 AM PT
Data Summary: Epinephrine absorption via neffy 2.0 mg under viral upper respiratory tract infection did not significantly impact the pharmacokinetics and pharmacodynamics. neffy 2.0 mg is expected to be a safe and effective option for the treatment of type I allergic reactions (including anaphylaxis) in patients experiencing upper respiratory tract infections.
About Type I Allergic Reactions including Anaphylaxis
Type I severe allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I severe allergic reactions. Of those, only 3.3 million currently have an active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency.
Posted In: SPRY
